Geode Capital Management
ELOX

Geode Capital Management’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

Geode Capital Management’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,588
Closed -$93.3K – 4812
2023
Q3 		$93.3K Sell
19,588
-671
-3% -$3.76K ﹤0.01% 4271
2023
Q2 		$78.8K Buy
20,259
+19
+0.1% +$122 ﹤0.01% 4402
2023
Q1 		$50.8K Buy
20,240
+44
+0.2% +$159 ﹤0.01% 4517
2022
Q4 		$36K Buy
20,196
+4
+0% +$19 ﹤0.01% 4678
2022
Q3 		$137K Buy
20,192
+132
+0.7% +$1.59K ﹤0.01% 4407
2022
Q2 		$214K Buy
20,060
+52
+0.3% +$718 ﹤0.01% 4220
2022
Q1 		$448K Buy
20,008
+57
+0.3% +$1.12K ﹤0.01% 3990
2021
Q4 		$558K Buy
19,951
+630
+3% +$27.5K ﹤0.01% 3989
2021
Q3 		$1.26M Buy
19,321
+6,138
+47% +$378K ﹤0.01% 3568
2021
Q2 		$1.05M Buy
13,183
+2,088
+19% +$174K ﹤0.01% 3568
2021
Q1 		$1.47M Buy
11,095
+601
+6% +$91.9K ﹤0.01% 3400
2020
Q4 		$1.67M Buy
10,494
+82
+0.8% +$10K ﹤0.01% 3175
2020
Q3 		$1.09M Buy
10,412
+487
+5% +$58.3K ﹤0.01% 3177
2020
Q2 		$1.2M Buy
9,925
+293
+3% +$33.2K ﹤0.01% 3089
2020
Q1 		$755K Buy
9,632
+978
+11% +$159K ﹤0.01% 3124
2019
Q4 		$2.55M Buy
8,654
+1,320
+18% +$266K ﹤0.01% 2863
2019
Q3 		$1.33M Buy
7,334
+552
+8% +$157K ﹤0.01% 3133
2019
Q2 		$2.7M Buy
6,782
+619
+10% +$260K ﹤0.01% 2757
2019
Q1 		$2.88M Buy
6,163
+213
+4% +$103K ﹤0.01% 2630
2018
Q4 		$2.86M Buy
5,950
+541
+10% +$298K ﹤0.01% 2558
2018
Q3 		$3.69M Buy
5,409
+341
+7% +$218K ﹤0.01% 2558
2018
Q2 		$3.46M Buy
+5,068
New +$3.28M ﹤0.01% 2540

Other funds holding ELOX

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Geode Capital Management's ELOX Position: Q4 2023 in Review

Geode Capital Management sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q4 2023, closing a stake of 19,588 shares — an estimated $93.3K sold.

Geode Capital Management first reported a position in ELOX in Q2 2018 and held it in 22 quarters. The position peaked at $3.69M in Q3 2018. 4 funds tracked by Wall St. Rank hold ELOX as of Q4 2023.

  • Geode Capital Management reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Geode Capital Management sold 19,588 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $93.3K.
  • Geode Capital Management first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
  • Geode Capital Management's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $3.69M in Q3 2018.
  • 4 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Geode Capital Management's 13F filing for Q4 2023, filed 13 Feb 2024.